tbuckley/cabot-search huggingface dataset:
The daily costs of chemotherapy-associated adverse events: A cluster-based analysis
Authors: J. H. Silber, S. J. Ross, J. I. Mathew, O. Even-Shoshan, K. R. Fox, M. H. Weiner
Journal: Journal of Clinical Oncology (2005)

6001 Background: Chemotherapy-associated adverse events (C-AEs) including neutropenia (N), anemia (A), thrombocytopenia (T), mucositis (M) and dehydration (D) are common and associated with increased hospital costs. However, C-AEs often occur in clusters, and as a consequence, it makes little clinical sense to discuss the costs associated with a single C-AE in isolation from other C-AEs. Methods: This study estimates the costs of inpatient and outpatient C-AEs based on a new approach to classifying C-AEs - the clinically relevant C-AE cluster. The study population included all cancer patients receiving chemotherapy (N=2,067) during August 1, 2000 and July 31, 2001 at The University of Pennsylvania Health System. For these patients, C-AE clusters were determined using clinical algorithms based on the start and end dates of defined adverse events and dates of chemotherapy administration. Regression models were developed using a loglinear variance adjusted estimation procedure, to better estimate the daily costs associated with the presence of these AE clusters, adjusting for age, sex, cancer diagnosis, metastatic disease, chemotherapy regimen, and comorbidities including AIDS,congestive heart failure, angina, arrhythmia, hypertension, asthma, renal failure, diabetes, and other conditions. Results: The presence of increasingly complex clusters increased the daily cost of hospitalization. The cost of an adjusted hospital day with N alone was $1704 (95% CI 1189 to 2220), and the adjusted daily hospital cost for A was $2035 (1863 to 2207), while a hospital day with A+N+T was $2381 (2190 to 2586), and A+N+T+D was $2852 (2314 to 3389). A hospital day with M alone was $910 (-691 to 2511), while M + (N and/or A,T) increased the costs to $2001 (1733–2272). Conclusions: Chemotherapy associated AEs often occur in clusters. Observing these clusters provides an excellent method for improving the estimate of expected costs from hospitalization. Models incorporating clinically meaningful C-AE clusters can be utilized to both estimate the expected total costs of chemotherapy-associated AEs and to explore more rational utilization of supportive care interventions aimed at reducing C-AEs. (Funded by a grant from Amgen, Inc.) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen
MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study
Authors: T. J. Hobday, J. Rubin, K. Holen, J. Picus, R. Donehower, R. Marschke, W. Maples, R. Lloyd, M. Mahoney, C. Erlichman
Journal: Journal of Clinical Oncology (2007)

4504 Background: Treatment options for metastatic NET, including islet cell carcinoma (ICC) and carcinoid tumor (CT), are limited. These tumors frequently express vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet derived growth factor receptor receptor-β (PDGFR-β). Sorafenib, a small-molecule inhibitor of the VEGFR-2 and PDGFR-β tyrosine kinase domains, is a rational targeted therapy to evaluate in NET. Methods: Eligibility criteria included: ECOG PS = 2, = 1 prior chemotherapy, good organ function and signed informed consent. Prior interferon and prior or concurrent octreotide at a stable dose were allowed. Pts unable to take oral medications, with uncontrolled hypertension or with symptomatic coronary artery disease were excluded. Pts received sorafenib 400 mg po BID. Primary endpoint was response by RECIST in two cohorts (ie, CT and ICC) using separate 2-stage phase II designs. Results: 93 pts were enrolled: (50 CT, 43 ICC). For pts evaluable for the primary endpoint, 4 of 41 (10%) CT pts and 4 of 41 (10%) ICC pts had a PR. There were 3 minor responses (MR = 20–29% decrease in sum of target lesion diameters) in CT pts and 9 MRs in ICC pts for PR+MR rate of 17% for CT pts and 32% for ICC pts. For pts evaluable, 6-month progression-free survival was observed in 8/20 CT and 14/23 ICC pts. Grade 3–4 toxicity occurred in 43% of pts, with skin (20%), GI (7%) and fatigue (9%) most common. Translational studies from tumor tissue will be presented. Conclusions: Sorafenib at 400 mg po BID has modest activity in metastatic neuroendocrine tumors, with frequent grade = 3 toxicity. Supported by NOI CM6225. No significant financial relationships to disclose.
Oncogenic Water-Soluble Polycations. I. Induction of Sarcomas in Mice by Diethylaminoethyl-Dextran
Authors: J. M. Rice, J. K. Davidson, R. M. Madison, E. W. Kingsbury, W. Turner
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Oncogenic Water-Soluble Polycations. I. Induction of Sarcomas in Mice by Diethylaminoethyl-Dextran Get access J. M. Rice, J. M. Rice National Cancer Institute, Microbiological Associates, Inc., and Bionetics Research Laboratories7, Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar J. K. Davidson, J. K. Davidson National Cancer Institute, Microbiological Associates, Inc., and Bionetics Research Laboratories7, Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar R. M. Madison, R. M. Madison National Cancer Institute, Microbiological Associates, Inc., and Bionetics Research Laboratories7, Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar E. W. Kingsbury, E. W. Kingsbury National Cancer Institute, Microbiological Associates, Inc., and Bionetics Research Laboratories7, Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar W. Turner W. Turner National Cancer Institute, Microbiological Associates, Inc., and Bionetics Research Laboratories7, Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 2, February 1973, Pages 387–401, https://doi.org/10.1093/jnci/50.2.387 Published: 01 February 1973 Article history Received: 04 August 1972 Accepted: 19 October 1972 Published: 01 February 1973
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter]
Authors: R Storb, M Pepe, HJ Deeg, C Anasetti, FR Appelbaum, W Bensinger, CD Buckner, RA Cliff, K Doney, J Hansen
Journal: Blood (1992)
Posttraumatic Stress and Prolonged Grief After the Sudden Cardiac Death of a Young Relative
Authors: Jodie Ingles, Catherine Spinks, Laura Yeates, Kevin McGeechan, Nadine Kasparian, Christopher Semsarian
Journal: JAMA Internal Medicine (2016)

This cross-sectional study assesses psychological functioning, including prolonged grief and posttraumatic stress symptoms, and identifies factors that correlate with adverse outcomes after the sudden cardiac death of a young relative.
Experimental Determination of Absorbed Dose from X-Rays Near the Interface of Soft Tissue and Other Material
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial
Authors: Carsten Weishaupt, Anke Strölin, Birgit Kahle, Alexander Kreuter, Stefan W Schneider, Joachim Gerss, Maria Eveslage, Attyla Drabik, Tobias Goerge
Journal: The Lancet Haematology (2016)
구연 : HBsAg이 소실된 환자의 간조직내 B형 간염 바이러스 염기서열 분석 및 임상적 의의
Authors: 장혜영, 김균환, 전재윤, 박준용, 안상훈, 문영명, 한광협
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 과거에는 B형 간염바이러스의 표면항원(HBsAg)의 소실이 HBV 감염으로부터의 회복을 의미해 왔으나 최근 분자생물학적 진단 방법의 발달로 인하여 적은 양이지만 HBV DNA가 간을 비롯한 체내에 존재한다는 것이 확인 되었다. 하지만 그 기전에 대해서는 아직까지 불분명한 상태이므로 본 연자 등은 추적 관찰 중 HBsAg이 소실된 환자들의 조직을 분자 생물학적 실험을 통해 분석하였다. 대상과 방법: 총 430명의 만성 HBsAg 보유자로부터 항원이 소실된 22명의 간조직을 얻어 분석하였고 이중 3명은 항원 소실 전후의 조직을 얻을 수 있었다. 22명중 2명은 인터페론을, 1명은 라미부딘을 치료 받았었다. 모든 간조직에서 HBV DNA를 추출하여 major hydrophilic region(MHR)과 HBsAg부위를 control vector에 cloning하였다. 자동염기서열분석법으로 S gene의 돌연변이와 아형을 확인하고 HepG2 cell에 transfection시킨 후 in vitro transcription/translation을 통한 HBsAg의 정량적 분석과 ELISA를 이용한 HBsAg/anti-HBs binding assay를 시행하였다. 또한 PCR방법을 통해 core promoter/precore 변이를 알아보았다. Real-time PCR은 HBV의 replicative form인 cccDNA의 정량을 위하여 시행되었다. 결과: Real-time PCR 결과 모든 조직에서 HBV의 cccDNA가 검출되어 혈청 내에서 HBsAg이 검출 되지 않는다 해도 간 조직에는 바이러스의 복제가 미약하나마 이루어지고 있다는 것을 알 수 있었다. MHR의 염기서열분석에서 T123S, M123I/N, I126L,C139R 그리고 D144E 변이가 6명에서 발견되었는데 특히 C139R 또는 D144E의 변이를 가진 군은 간세포내에 cccDNA가 많이 존재함에도 불구하고 낮은 항원성을 나타내었는데 이는 a-determinant 돌연변이로 인한 anti-HBs와 결합력 감소에 의한 것으로 보였다. 인터페론을 투여한 환자 중 한명은 225번의 아미노산인 티로신의 결손으로 HBsAg의 세포질내로 배출이 감소되어 HBsAg 검출이 안 되었음을 확인하였다. 라미부딘 투여 환자에서는 간세포에서 낮은 양의 cccDNA가 검출되어 실제로 HBsAg분비가 거의 소실 되었음을 알 수 있었다. Core promoter의 전사 인자 결합 부위에 A1762T와 G1764A변이는 혈청 HBeAg감소와 세포내 cccDNA감소와 동반되었는데 HBsAg소실과는 연관성이 없었다. 흥미롭게도 HBV 아형의 분석결과 HBsAg소실 환자들의 대부분이 ayw형 이었고 우리나라에서 흔한 adr형은 관찰되지 않았다. 결론: 만성 B형 간염 환자에서 HBsAg이 소실된 경우, HBV의 복제능 상실 외에도 돌연변이에 의한 HBsAg 항원성의 변화, HBsAg의 세포질내로 분비 장애가 항원 검출에 영향을 줄 수 있음을 확인하였다.
Apoptotic genes as a prognostic factor in penile epidermoid carcinoma
Authors: P. C. Novais, A. A. Paula, A. A. Rodrigues, D. F. Barione, F. M. Peria, D. P. Tirapelli, S. Tucci, A. J. Cologna, A. C. Martins, L. F. Tirapelli
Journal: Journal of Clinical Oncology (2009)

e22208 Background: The penile cancer is a rare condition in European men. The treatment can cause physiological and/or psychological problems in patients. The comprehension of the disease behavior can provides new, non-invasive therapeutic interventions. For this reason, the protein expression of apoptotic genes (caspase-3, caspase-8, bcl-2) were analysed with the immunohistochemistry technique, correlating with tumor grade (I, II and III) and with the patient survival in order to understand the basic mechanism of tumoral transformation. It is beyond doubt that studies related with penile cancer and its mechanism of apoptosis is scarce in the literature. Therefore, this study can contribute with information about this disease. Methods: The immunohistochemistry reactions on 50 samples of squamous cell carcinoma were carried out with the avidina-biotina-imunoperoxidase method with antigen recovery. The analyses were made using the graduation method ‘in crosses‘ (0 to 4 crosses - no stain to more than 75% of positives cells) and in categories (low, intermediate, high) of the cytoplasm immunoreactivity of the epidermoide penile carcinoma cells. Results: It was observed a statistically significant difference when the expression of caspase-3 were compared with the grades I and II of the tumor (p=0.0010) and when comparing the patient survival with the grades I and II of the tumor (p=0.0212). The protein expression of caspase-3 and caspase-8 was lesser in relation to bcl-2, suggesting that the apoptotics rate in this carcinoma is low. The higher expression of the anti-apoptotic protein bcl-2 suggests a higher preservation of the tumoral cells. Conclusions: The analysis did not showed correlation between the proteins expression with the survival curve of patients. No significant financial relationships to disclose.
Effective use of teachable moment, for tobacco cessation, at coronary care unit
Authors: Amber Ashraf, Saadia Ashraf, Mukhtiar Zaman
Journal: European Respiratory Journal (2013)

Background: Tobacco Cessation after Acute Coronary Syndrome(ACS) is associated with a significant reduction in mortality,so quitting tobacco advice at this moment can be beneficial.

Objective: To determine the effectiveness of tobacco cessation advice, in patients admitted with chest pain,at coronary care unit(CCU).

Methodology: This study was conducted from jan 2008 - june 2009, at CCU,Khyber Teaching Hospital, among tobacco user patients who were admitted with chest pain.Participants who expressed interest in quitting tobacco had received tobacco cessation advice, which consisted of onsite counseling plus up to three follow up booster session at 1,3&6months in cardiology OPD.Main outcome measures in the form of continous abstinence at 1,3,6months determined by self reporting.

Result: Total of 1165 patients were presented with chest pain &469 were found to be tobacco user &willing toparticipate.84% were male &15% were female. Niswar addict were 31%,26% were cigarette smokers, 15% were passive smokers &26% used both.Out of tobacco users,40,26 & 19% patients had acute myocardial infaraction(MI),Unstable Angina(UAP)& NonSTelevation MI (NSTEMI) whereas rest of 14% patients had other diagnosis. All 469 patients had received tobacco quit advice during there stay in CCU. After discharge these were followed at 1,3 &6 months in OPD. At end of study, 26% participants maintained complete abstinence from tobacco use, 34% had lost to follow up, 21% had reduced tobacco use but 20% countinue with tobacco use in different forms.

Conclusion: Coronary Care Unit setting can be used as an effective teachable moment for tobacco cessation, provided repeated councelling at follow-up visits.
Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)
Authors: J. S. De Bono, G. Attard, A. H. Reid, C. Parker, M. Dowsett, R. Mollife, T. A. Yap, A. Molina, G. Lee, D. Dearnaley
Journal: Journal of Clinical Oncology (2008)

5005 Background: AA is an oral irreversible inhibitor of CYP17 (17α-hydroxylase/ C17,20-lyase) and of androgen synthesis under evaluation for the treatment of CRPC pts. Methods: Since 2005 CRPC pts who have failed androgen deprivation therapy (ADT) have been enrolled into two parallel trials of AA: i) Phase I/II study in chemo-naïve CRPC and ii) Phase II study in CRPC post-docetaxel. Both Phase II trials utilized a two-stage Simon design with Ho of 10% and Ha of 30%, α = 0.05; β = 0.1 and PSA response (≥50% decline) by PSAWG criteria as the primary endpoint for response evaluation. Results: 86 pts were treated and 72 are evaluable for response. In the 1st study AA was well tolerated at all dose levels (250–2000 mg) with no DLT; 1000 mg was the selected Phase II dose based on PK-PD evaluation. Both Phase II trials have rejected the null hypothesis with the ≥50% PSA response exceeding 60% in the chemo-naïve cohort and exceeding 40% in the taxane treated cohort. Chemo-naïve pts (n=44) received a median of 3 prior hormonal treatments, with bone metastases in 70% of pts and measurable disease by RECIST in 21 pts; 12/21 pts had a PR by RECIST. Median time to PSA progression (TTPP) was 252 days. 14 pts on AA received >12 cycles (48 weeks). In post-docetaxel pts (n=28), > 80% had bone metastases and 18/28 were evaulable by RECIST, with 4 achieving PR; 11 pts remain on study >6 months and 5 pts > 12 cycles. Median TTPP is 167 days. Improved symptoms, decreased analgesic requirement and falls in circulating tumor cell counts have been observed. Mechanism-based AEs secondary to mineralocorticoid excess consisting primarily of Grade 1–2 hypertension, hypokalemia and fluid retention were reversible with concomitant eplerenone or low-dose corticosteroids. Using an ultra-sensitive serum testosterone (T) assay, significant T suppression, beyond that achieved by conventional ADT was detected. Conclusions: AA is well tolerated and produces encouraging anti-tumor activity in CRPC. These results support emerging data indicating that CRPC frequently remains hormone driven despite progression following ADT and docetaxel-based chemotherapy. Randomized Phase III trials of AA will soon be initiated. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Cougar Biotechnology Cougar Biotechnology
Postoperative radiotherapy in the treatment of uterine sarcomas: Long-term results and analysis of prognostic factors
Authors: B. Atalar, S. Okkan, G. Meral, I. Sahinler, Z. Calay, S. Koca, G. Atkovar
Journal: Journal of Clinical Oncology (2004)

9045 Background: To evaluate the role of postoperative radiotherapy in local control and survival and to identify important prognostic factors in uterine sarcomas. Methods: Sixty patients with uterine sarcomas treated with postoperative radiotherapy during the period 1979–2001 were retrospectively analyzed. The median age was 49.5 years (24–78). Histologic type was leiomyosarcoma (LMS) in 24 patients, endometrial stromal sarcoma (ESS) in 19 patients, and mixed müllerian tumor (MMT) in17 patients. The stage distribution was : Stage I: 60%, II: 11.7%, and III: 28.3%. Forty patients were treated with simple hysterectomy and 14 patients with radical hysterectomy. In 6 patients surgery was insufficient. All patients were treated with external pelvic irradiation. The pelvic dose range was 45.6–54.6 Gy. Intracavitary brachytherapy was given in 9 patients. Pelvic control (PC), disease-free survival (DFS), distant metastasis-free survival (DMFS) and overall survival (OS) were calculated. Age, stage, histology, grade, tumor size, type of surgery, residual disease, duration between surgery and radiotherapy and total treatment time were selected as a possible prognostic factors for PC and OS. Age, total treatment time, pelvic dose, dose per fraction, boost dose, intracavitary brachytherapy and acute side effects were analyzed as probable prognostic factors for late complications. Results: Median follow-up was 84 months. The 10-year PC, DFS, DMFS and OS rates were 84%, 64%, 67.3% and 63.9 respectively. The 10-year OS rates for ESS, LMS and MMMT were found 84.2%, 60%, and 51% respectively. Univariate analysis showed that age, residual disease, type of surgery and stage were the significant factors for PC; residual disease, type of surgery and stage were the significant factors for DMFS; stage was the only significant factor for DFS and OS. Total treatment time, pelvic dose, dose per fraction, and acute side effects were found significant factors for late complications. Conclusions: Although, our results suggest improved pelvic control in these patients, the role of postoperative radiotherapy should be tested by prospective randomized trials. No significant financial relationships to disclose.
Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS).
Authors: A. J. Wozniak, J. Garst, M. Jahanzeb, M. P. Kosty, R. Vidaver, S. Beatty, S. Teng, E. D. Flick, A. Sing, T. J. Lynch
Journal: Journal of Clinical Oncology (2010)

7618 Background: BV (Avastin) prolongs progression-free (PFS) and overall survival (OS) in advanced NSCLC. ARIES, a prospective OCS evaluating BV in a real world setting, includes pts underrepresented in randomized controlled trials (RCTs), i.e., pts ≥70y, with poor performance status (PS), or with CNS metastases (mets). Preliminary COs (effectiveness and safety) in ARIES subpopulations are presented. Methods: Pts with locally advanced nonsquamous NSCLC on first-line chemotherapy (CT) and BV enrolled. No prespecified treatments, doses or assessments. Data are collected electronically at baseline (BL) and quarterly (QU), including BV-targeted adverse events (AEs) and serious AEs (SAEs). Descriptive safety analyses were conducted for all pts and for subgroups. Median (med) PFS and OS are Kaplan-Meier estimates. Results: ARIES enrolled 1,970 NSCLC pts. Med follow-up at the 09/2009 data cut was 9.6 mo; 98% have ≥1 QU follow-up. Med PFS is 6.7 mo and OS is 13.6 mo for the entire cohort and were similar across subgroups except pts with PS≥2. The most common 1st-line CT is carboplatin/paclitaxel (CP). Pts ≥70y and pts with PS≥2 or CNS mets at BL generally used more nonplatin-containing CT and pemetrexed. AE rates across subgroups were similar to the overall cohort except for increased arterial thromboembolic events (ATE) in pts ≥70y and with PS≥2. No CNS bleeding events occurred in pts with CNS mets at BL. Conclusions: The COs (safety/effectiveness) of BV in pts ≥70y, or with PS≥2 or CNS mets are consistent with the known BV efficacy and safety profile. Pts with PS≥2 received less CP and had worse COs but not more AEs/SAEs. Pts ≥70y had COs similar to the overall cohort despite less doublet CT, suggesting that advanced age, poor PS, or CNS mets should not necessarily exclude pts from receiving BV therapy. All NSCLC pts (n = 1,970) Age ≥70 (n = 650) PS ≥2 (n = 182) CNS Mets(n = 150) Med PFS (mo) 6.7 6.8 5.8 6.0 Med OS (mo) 13.6 12.6 8.1 11.7 CP 1st-line CT, n (%) 1,215 (62) 382 (59) 107 (59) 82 (55) Severe pulmonary hemorrhage (PH), n (%) 15 (0.8) 2 (0.3) 2 (1) Gr 3-5 bleeding excluding PH, n (%) 52 (3) 20 (3) 7 (4) ATEs, n (%) 35 (2) 20 (3) 6 (3) Gr 3-5 CNS bleed, n (%) 2 (0.1) 0 1 (0.5) 0 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech AstraZeneca, BIPI, Genentech, GlaxoSmithKline, Inifinity Pharma, Lilly, Merck, sanofi-aventis Inifinity Pharma, Roche Genentech, GlaxoSmithKline, Lilly, sanofi-aventis Genentech